Former Dow biotech Pfenex files for a $75 million IPO to fund development of wet AMD treatment

By
A A A

Pfenex, a biotech developing an alternative to Roche's Lucentis treatment for wet AMD, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. Lucentis generates over $4.3 billion annually for Roche, which manufactures and sells the drug in the U.S., and Novartis ( NVS ), which markets it outside the country. Pfenex is also developing candidates for other high-value protein therapeutics.

The San Diego, CA-based company was spun out of Dow Chemical ( DOW ) in 2009 and booked $11 million in collaboration revenue for the 12 months ended March 31, 2014. Pfenex plans to list on the NYSE under the symbol PFNX and initially filed confidentially on May 5, 2014. William Blair and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: NVS , DOW

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%
82%

Most Active by Volume

64,776,012
  • $117.60 ▼ 0.86%
53,107,118
  • $10.39 ▼ 1.05%
42,226,525
  • $17.10 ▼ 0.47%
36,916,182
  • $11.02 ▼ 0.36%
34,901,621
  • $40.75 ▼ 0.10%
31,489,542
  • $15.68 ▲ 0.06%
31,037,743
  • $75.63 ▲ 2.19%
29,604,587
  • $10.11 ▼ 0.69%
As of 11/25/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com